PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLamotrigine
Lamotrigine
Lamictal, Lamotrigine (lamotrigine) is a small molecule pharmaceutical. Lamotrigine was first approved as Lamictal on 1994-12-27. It is used to treat bipolar disorder, epilepsy, lennox gastaut syndrome, mood disorders, and partial epilepsies amongst others in the USA. It is known to target sodium channel protein type 2 subunit alpha.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
signs and symptoms pathological conditionsD013568
mental disordersD001523
Trade Name
FDA
EMA
Lamictal, Lamotrigine (discontinued: Lamictal, Lamotrigine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lamotrigine
Tradename
Company
Number
Date
Products
LAMICTALGSKN-020241 RX1994-12-27
4 products, RLD, RS
LAMICTAL CDGSKN-020764 RX1998-08-24
3 products, RLD, RS
LAMICTAL XRGSKN-022115 RX2009-05-29
6 products, RLD, RS
LAMICTAL ODTGSKN-022251 RX2009-05-08
4 products, RLD
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
lamictalNew Drug Application2023-02-09
lamotrigineANDA2025-01-15
lamotrigine erANDA2024-06-19
lamotrigine extended releaseANDA2022-01-14
lamotrigine lamotrigineANDA2024-11-17
subveniteANDA2024-11-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
epilepsyEFO_0000474D004827G40.9
lennox gastaut syndrome—D065768G40.81
seizuresHP_0002069D012640G40.4
partial epilepsiesEFO_0004263D004828—
bipolar disorderEFO_0000289D001714F30.9
mood disordersEFO_0004247D019964F30-F39
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Lamotrigine, Lamictal Xr, Glaxosmithkline Llc
86375122028-06-14DP
ATC Codes
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AX: Other antiepileptics in atc
— N03AX09: Lamotrigine
HCPCS
No data
Clinical
Clinical Trials
225 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Therapeutic equivalencyD013810——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLamotrigine
INNlamotrigine
Description
Lamotrigine is a member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6. It has a role as an anticonvulsant, an antimanic drug, an antidepressant, a non-narcotic analgesic, a calcium channel blocker, an excitatory amino acid antagonist, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor, an environmental contaminant, a xenobiotic and a geroprotector. It is a member of 1,2,4-triazines, a primary arylamine and a dichlorobenzene.
Classification
Small molecule
Drug classsodium channel blockers, signal transduction modulators
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
Identifiers
PDB—
CAS-ID84057-84-1
RxCUI—
ChEMBL IDCHEMBL741
ChEBI ID6367
PubChem CID3878
DrugBankDB00555
UNII IDU3H27498KS (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SCN2A
SCN2A
Organism
Homo sapiens
Gene name
SCN2A
Gene synonyms
HBA, NAC2, SCN2A1, SCN2A2
NCBI Gene ID
6326
Protein name
sodium channel protein type 2 subunit alpha
Protein synonyms
HBSC II, Sodium channel protein brain II subunit alpha, Sodium channel protein type II subunit alpha, sodium channel protein, brain type 2 alpha subunit, sodium channel, voltage-gated, type II, alpha 1 polypeptide, sodium channel, voltage-gated, type II, alpha 2 polypeptide, sodium channel, voltage-gated, type II, alpha subunit, voltage-gated sodium channel subtype II, Voltage-gated sodium channel subunit alpha Nav1.2, voltage-gated sodium channel type II alpha subunit
Uniprot ID
Q9BZD0
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lamotrigine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 17,901 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lamictal, Lamotrigine, Lamotrigine er, Lamotrigine extended release, Lamotrigine lamotrigine, Subvenite
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
78,078 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use